Medipharm Labs (TSX: LABS) continues to expand its international presence, this morning announcing that it has signed a white label supply agreement with DanCann Pharma A/S. The arrangement will see Medipharm export its white labeled product from its facilities in both Canada and Australia to that of Denmark.
DanCann Pharma, established in 2018 following regulatory changes in the country of Denmark related to the status of medical cannabis in the country, is focused on what it refers to as therapeutic cannabinoids. The company manufacturers and imports prescription and over the counter pharmaceuticals for pain patients that are covered until the pilot program for medical cannabis in Denmark.
While Medipharm was quick to press release the new agreement, details provided by the company are relatively slim. What is known about the contract is that it is for a two year period, during which time Medipharm will “supply a full range of specially formulated CBD and THC products.” These products will be white labelled for distribution by DanCann.
It’s unclear if there are any contractual minimums or maximums associated with the agreement, or the significance of the contract in terms of dollars.
Medipharm Labs last traded at $0.80 on the TSX.
.Information for this briefing was found via Sedar and Medipharm Labs. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
As the founder of The Deep Dive, Jay is focused on all aspects of the firm. This includes operations, as well as acting as the primary writer for The Deep Dive’s stock analysis. In addition to The Deep Dive, Jay performs freelance writing for a number of firms and has been published on Stockhouse.com and CannaInvestor Magazine among others.